Influence of BRCA pathogenic variants in the benefit of secondary cytoreductive surgery.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6076
Abstract: 6076Background: Germline BRCA pathogenic variants are present in 15% to 25% of ovarian carcinoma patients. These tumors are more sensitive to platinum and PARP inhibitor therapy and have a better p... read more here.
Keywords: pathogenic variants; variants benefit; benefit secondary; influence brca ... See more keywords